MB Venture Partners
Gary Stevenson, Co-Founder and Managing Partner
Gary Stevenson co-founded MB Venture Partners in 2001 after six years in healthcare investment banking and equity research. At MBVP, he has raised $120 million in committed capital to four funds and invested in more than 50 start-ups, most of which are focused on product solutions for musculoskeletal disease. He also spent seven years in a variety of general management roles with Abbott Laboratories. Gary holds an undergraduate degree in accounting from the University of Missouri. He also received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University. He is a certified public accountant and a chartered financial analyst. Gary is a board member or observer for several MBVP portfolio companies. Medtronic, Smith + Nephew, Zimmer Biomet, and Wright Medical have each acquired MBVP-funded start-ups. This will be his 18th year to host the MNVC.
CrossRoads Extremity Systems
Vernon Hartdegen, President & CEO
Chad Hollis, Vice President of R&D
Headquartered in Memphis, TN, CrossRoads was founded in 2014 by Glen Coleman, Vernon Hartdegen and Chad Hollis. The Company’s mission is to develop and commercialize breakthrough technologies in the orthopedic extremity sector that improve the operating room experience and patient outcomes through simplicity and accuracy for the surgeon, and sustainability and cost reduction for healthcare institutions. CrossRoads’ Staple Compression Plate™ technology is the only technology on the market today to simultaneously offer enhanced stability with continuous compression, optimizing conditions for bone healing in fusion procedures. The Company leverages this technology in a broad range of procedure-specific, sterile-packed implants and instrumentation systems cleared for both lower and upper extremity indications. The Company’s EcoSMART® Instrument Service provides customers with gamma sterilized, reusable instruments for every surgical case and post-surgery recovery and processing of those instruments. EcoSMART® reduces the inefficiencies of traditional reusable instrument trays.
Mike Mogul, President and Managing Director
Mike Mogul is President and Managing Director of HealthpointCapital. Prior to Healthpoint, Mike was last President, Chief Executive Officer and Director of DJO Global, a $1 billion firm in the Orthopedic sector owned by Blackstone, and market leading in non-operative segments including Bracing and Physical Therapy equipment. DJO was also the fastest growing firm in Total Joint implants and Consumer Sports Medicine under his leadership. Prior to joining DJO, Mike served as Group President, Orthopaedics for Stryker Corp. managing Stryker’s global orthopaedic businesses, which represented approximately $3 billion in revenue. Additionally, in his 22 years in the musculoskeletal space at Stryker, Mike served as Managing Director of all of Stryker’s divisional segments in Germany, Austria and Switzerland. Mike is Chairman of the Board of Crossroads Extremity Systems, Chairman of the Board of IlluminOss, and a Board Member of ProSomnus Sleep Technologies. Mike received a Bachelor of Science degree from the University of Colorado and has attended the Advanced Management Program at the Harvard Business School.
Laing Rikkers, Managing Director
Laing Rikkers is an experienced investor and executive with a track record of building successful businesses. As a member of the Investment Committee and an advisor to portfolio companies at HealthpointCapital, her principal role is in identifying investment opportunities, determining strategies and developing organizations. Ms. Rikkers has been with HealthpointCapital since 2004 and prior spent 10 years in management positions at Amerada Hess Corporation, the Walt Disney Company and New York-Presbyterian Hospital focused on Organizational Development and Human Resources. Ms. Rikkers is a Director and founding Chairman of ProSomnus Sleep Technologies, and was formerly a Director of BioHorizons, Inc. and MicroDental Laboratories, Inc. She is the Chair of the Salk Institute Council, and a Cabinet member of the Salk Excellerators at the Salk Institute for Biological Studies. She is also a Trustee of the Pacific Ridge School. Ms. Rikkers received a B.A. from Harvard College and an M.A. in Organizational Psychology from Columbia University.
IlluminOss Medical, Inc.
Bob Rabiner, Chief Technical Officer
Mike Mogul, Board Member
IlluminOss Medical, Inc. is a privately held, commercial-stage medical device company offering a unique, minimally invasive technology for the repair and stabilization of fractures in poor quality weakened bone; particularly applicable for osteoporotic and pathologically compromised bone. The IlluminOss system utilizes a light-curable liquid monomer which is infused and contained within a conformal balloon sized to the patient’s anatomy and then illuminated with visible blue light converting the liquid to a strong hardened polymer, creating a patient-conforming intramedullary implant. The cured implant conforms to the shape of the patient’s intramedullary canal, providing rapid strength and stability to the compromised bone. Designed as a stand-alone implant, however should supplemental fixation devices be needed, they can be placed anywhere along the implant. The speed, simplicity and minimally invasive procedure has permitted the majority of patients treated with IlluminOss to return to their daily living activities far sooner and with less use of post-operative pain medications. Used in over 4000 patients in Europe, IlluminOss has been recently launched in the United States for general trauma use. The IlluminOss system is both FDA-cleared and CE marked for a wide variety of anatomical sites, with further indications pending. IlluminOss is headquartered in East Providence, RI.
Matt Hedrick, Chief Executive Officer
Jeff Shepherd, Vice President of Sales
Nanovis is a unique technology company that discovers, develops, and commercializes innovative nanotechnology platforms designed for improving bone growth and fighting infection. Nanovis’s bioceramic nanotube surface is FDA cleared with a differentiated label, is well-proven and is ready to upgrade any orthopedic implant made of titanium or titanium alloy. Nanovis’s Nano FortiCore interbodies also utilize a deeply porous titanium scaffold (licensed from Sites Medical). Nanovis’s advanced bioceramic bactericidal nanotube surface technology and Nanovis’s breakthrough localized infection technology targeting multi drug resistant bacteria is in pre-clinical studies.
J.P. Peltier, Global Head – Healthcare Investment Banking
J.P. Peltier is a Managing Director and Global Group Head of Piper Sandler healthcare investment banking. Peltier has more than 22 years of healthcare investment banking experience at Piper Sandler. Peltier leads a team of more than 100 healthcare investment banking professionals in offices around the world. Peltier has extensive experience advising clients on mergers and acquisitions, public and private equity options and other strategic alternatives. Peltier’s prior experience includes five years at HomeServices of America, a Berkshire Hathaway subsidiary, where he served as vice president of corporate development and president of the mortgage banking division. Peltier graduated from the University of St. Thomas and received a Master of Business Administration degree from the J.L. Kellogg School of Management at Northwestern University. Peltier is a member of the Board of Governors of Science Museum of Minnesota.
Charles Hamilton, Director, Healthcare Investment Banking
Charles Hamilton is a Director in the Piper Sandler healthcare investment banking group and a senior partner of the medical technology team. Hamilton has 20 years of healthcare investment banking and capital markets experience, and has completed over 75 M&A and capital markets transactions on behalf of his medical technology clients at Piper Sandler. Hamilton joined Piper Sandler in 2008 from Thomson Financial, where he was a senior investor relations consultant to publicly traded companies. Previously, Hamilton was a member of the Chicago Board of Trade and an open outcry market maker for commodities options contracts. Earlier in his career, he conducted research in gene therapies for vascular disease at The University of Chicago Hospitals Section of Vascular Surgery. Hamilton graduated from The University of Chicago with a bachelor’s degree in cell and molecular biology, and received a Master of Business Administration with concentrations in analytic finance and accounting from The University of Chicago Booth School of Business.